Weekly Recap | SPDR S&P Biotech +0.33%, mixed tape within biotech
I'm LongbridgeAI, I can summarize articles.SPDR S&P Biotech (XBI) rose 0.33% this week to close at $156.72, while the S&P 500 fell 0.08%, leaving XBI about 0.41 percentage points ahead of the benchmark. The week was choppy, with an intraweek range of 4.99%. The ETF started Monday by edging up to $157.60, pulled back to $154.03 on Tuesday, touched a weekly low of $152.50 on Wednesday, then rebounded to a weekly high of $160.33 on Thursday before easing to $156.72 on Friday. The close was slightly above the prior week’s $156.20.
The Week
SPDR S&P Biotech (XBI) rose 0.33% this week to close at $156.72, while the S&P 500 fell 0.08%, leaving XBI about 0.41 percentage points ahead of the benchmark. The week was choppy, with an intraweek range of 4.99%. The ETF started Monday by edging up to $157.60, pulled back to $154.03 on Tuesday, touched a weekly low of $152.50 on Wednesday, then rebounded to a weekly high of $160.33 on Thursday before easing to $156.72 on Friday. The close was slightly above the prior week’s $156.20.
Key Events
The biotech complex was driven by a handful of names that matter to XBI’s passive basket. Moderna gained after Phase III melanoma success, and some call options jumped 381% in a single day. Natera reported a lung cancer MRD study linking Signatera results to three-year recurrence-free survival in 1,129 patients, and the stock rose 12.3% on the week. Twist Bioscience climbed 31.26% after a tie-up with Lilly’s TuneLab on AI-driven drug discovery, though BWS Financial kept a sell rating with a $45 target. Halozyme swung on plans for a $1.3 billion convertible bond offering, then hit a record high after pricing. Iovance Biotherapeutics was up 307% for the year, and Roivant Sciences wrapped up its annual meeting with governance approvals. The common thread was cancer diagnostics, vaccines and AI-enabled drug development.
The Week Ahead
No XBI constituents report earnings next week, and the macro calendar is light. Tuesday brings the Richmond Fed manufacturing index, with a prior reading of 4. Thursday includes jobless claims, the current account balance and new home sales, with the annualised rate expected at 608,000 versus 607,000 prior. Any shift in rate-related sentiment could ripple into growth-sensitive assets.
In Short
XBI eked out a weekly gain and outperformed the S&P 500, but the tape was two-sided. Cancer vaccines, liquid biopsy and AI-driven drug discovery drew attention, while Halozyme’s convertible issuance stirred volatility. The latest-session money flow snapshot shows small-lot money as a net buyer by a wide margin. With the 60-day range spanning $143.775 to $169.89, XBI sits near the middle of that band at $156.72. The next test is how macro data affects rate expectations and whether the week’s pipeline themes hold up.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.